Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition

Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma ... Read More